权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A sleep electroencephalography biomarker predicting Alzheimer's disease pathology

预测阿尔茨海默病病理的睡眠脑电图生物标志物

基本信息

批准号：
9194204
负责人：
Matthew P Walker
金额：
$ 412.23万
依托单位：
UNIVERSITY OF CALIFORNIA BERKELEY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-15 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9194204
关键词：
Address Adult Advocate Alzheimer&apos s Disease Alzheimer&apos s disease risk Amyloid Amyloid beta-Protein Awareness Biological Markers Clinical Cognitive Communities Data Dementia Development Diagnostic Disease Disease Progression Early Diagnosis Elderly Electroencephalography Future Genetic Global Change Goals Gold Health Health Policy Home environment Human Impairment Individual Intercellular Fluid Intervention Laboratories Longevity Measures Medical Molecular Onset of illness Pathology Polysomnography Positron-Emission Tomography Prevalence Preventive Intervention Process Public Health Publishing REM Sleep Risk Rodent Rodent Model Sensitivity and Specificity Severities Sleep Sleep Fragmentations Slow-Wave Sleep Staging Symptoms Testing Time Wrist abeta accumulation abstracting actigraphy age related apolipoprotein E-4 base cerebral atrophy community setting density design glymphatic system improved in vivo indexing interstitial neuropsychological non rapid eye movement novel pre-clinical risk variant tool true biomarker

项目摘要

Project Summary/Abstract: Early biomarkers of Alzheimer's disease are urgently required for at least three reasons: (i) to determine which individuals are at greatest Alzheimer's disease risk, thereby (ii) offering preventative intervention, pre-disease onset, and (iii) further allowing nascent treatment intervention as early as possible in the disease process. All three goals demand a sensitive, non-invasive, affordable, accessible biomarker of Alzheimer's disease pathology/progression. Addressing these needs, we propose to test the hypothesis that a unique NREM sleep EEG signature provides a candidate early biomarker of Aβ pathology, one that may accurately track and forecast Alzheimer's disease risk and Alzheimer's disease pathophysiological progression. If correct, the proposal would establish a novel, inexpensive, and early diagnostic tool for determining Alzheimer's disease risk and pathology progression before clinical symptoms emerge, and one that is suitable for community settings. Moreover, such data would motivate an increased medical awareness regarding the importance of treating sleep difficulties across the lifespan, and further motivate the development (clinical or commercial) of sleep-based interventions that improve adult sleep and thus reduce Alzheimer's disease prevalence and its societal burden. More generally, such findings would argue for improved public health policies advocating for sufficient quality sleep throughout adulthood—a memorandum that may lower dementia risk and maintain cognitive health across the populous.

项目摘要/摘要：至少三个迫切需要阿尔茨海默病的早期生物标志物原因：(i) 确定哪些人面临最大的阿尔茨海默病风险，从而 (ii) 提供预防性干预、疾病发作前，以及 (iii) 进一步允许尽早进行新生治疗干预尽可能在疾病过程中。所有这三个目标都需要一个敏感的、非侵入性的、负担得起的、可访问的阿尔茨海默病病理/进展的生物标志物。为了满足这些需求，我们建议测试假设独特的 NREM 睡眠脑电图特征提供了 Aβ 病理学的候选早期生物标志物，一种可以准确跟踪和预测阿尔茨海默病风险和阿尔茨海默病的方法病理生理进展。如果正确，该提案将建立一种新颖的、廉价的、早期的用于在出现临床症状之前确定阿尔茨海默病风险和病理进展的诊断工具出现，并且适合社区环境。此外，此类数据将激励更多关于治疗整个生命周期睡眠困难重要性的医学意识，以及进一步激励改善成人睡眠的基于睡眠的干预措施的开发（临床或商业）从而减少阿尔茨海默病的患病率及其社会负担。更一般地说，这样的发现会主张改善公共卫生政策，提倡全程充足的优质睡眠成年期——一份可能降低痴呆风险并保持整个认知健康的备忘录人口众多。